Age-Related Macular Degeneration Epidemiology Analysis and Forecast, 2021-2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Age Related Macular Degeneration Market  Overview

In 2021, there were 79,030,963 total prevalent cases of Age Related Macular Degeneration Market (AMD). The cases are expected to rise at an AGR of more than 1% during 2021-2031. Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly. AMD is classified into three stages: early AMD, intermediate AMD, and late AMD. Late AMD is the advanced stage of AMD, which is characterized by the presence of late dry AMD or late wet AMD. According to a meta-analysis study, the pooled prevalence of any AMD was reported to be a share among adults ages 45–85 years. In addition to the high prevalence of the condition, AMD is also associated with severe disability and has a major impact on the quality of life and emotional well-being.

AMD Epidemiology Market Outlook, 2021-2031 (Total Prevalent Cases)

AMD

For more insights into the AMD Epidemiology market forecast, download a free report sample

AMD epidemiology market research report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AMD, each segmented into early AMD and late AMD and broken down by sex and age (50–59 years, 60–69 years, 70–79 years, and 80 years and older). The total and diagnosed prevalent cases of late AMD are further segmented into late dry AMD and late wet AMD. The report also includes the total prevalent cases and diagnosed prevalent cases of geographic atrophy (GA) in these markets.

Total no. of Cases 79,030,963
AGR% (2021-2031) >1%
Key Segments Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and GA

AMD Market by Segments

The key segments in the AMD market are Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and GA. In 2021, the US accounted for a significant share of the total prevalent cases of early AMD in the 7MM. However, Spain is expected to have the highest AGR in the forecast period. Similarly for Late AMD, again the US has the highest number of prevalent cases among the 7MM. In case of Late Dry AMD, the UK is expected to have the highest AGR during the forecast period. In case of Late Wet AMD, the US has a significant percentage of cases, and the UK is expected to have the highest AGR. Similarly in case of GA, the UK is expected to have the highest AGR during the forecast period.

Scope

  • This report provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report also includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of AMD, each segmented into early AMD and late AMD and broken down by sex and age (50–59 years, 60–69 years, 70–79 years, and 80 years and older). The total and diagnosed prevalent cases of late AMD are further segmented into late dry AMD and late wet AMD. The report also includes the total prevalent cases and diagnosed prevalent cases of geographic atrophy (GA) in these markets. The forecast is supported by robust, country-specific data that was obtained from various authentic sources such as research articles published in peer-reviewed journals. In addition, in the case of data scarcity, GlobalData epidemiologists used primary market research (PMR) data wherever necessary.
  • The AMD epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

  • The AMD Epidemiology series will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global AMD market.
  • Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for AMD therapeutics in each of the markets covered.
  • Understand magnitude of AMD by early AMD and late AMD. Late AMD are further segmented into late dry AMD and late wet AMD.

Table of Contents

| About GlobalData

1 Age-Related Macular Degeneration: Executive Summary

1.1 Catalyst

1.2 Related Reports

1.3 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 7MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD

2.4.4 Forecast Assumptions and Methods: Total Prevalent Cases of GA

2.4.5 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and GA

2.5 Epidemiological Forecast for AMD (2021–31)

2.5.1 Total Prevalent Cases of AMD

2.5.2 Age-Specific Total Prevalent Cases of AMD

2.5.3 Sex-Specific Total Prevalent Cases of AMD

2.5.4 Total Prevalent Cases of Early AMD

2.5.5 Total Prevalent Cases of Late AMD

2.5.6 Total Prevalent Cases of Late Dry AMD

2.5.7 Total Prevalent Cases of Late Wet AMD

2.5.8 Total Prevalent Cases of GA

2.5.9 Diagnosed Prevalent Cases of AMD

2.5.10 Age-Specific Diagnosed Prevalent Cases of AMD

2.5.11 Sex-Specific Diagnosed Prevalent Cases of AMD

2.5.12 Diagnosed Prevalent Cases of Early AMD

2.5.13 Diagnosed Prevalent Cases of Late AMD

2.5.14 Diagnosed Prevalent Cases of Late Dry AMD

2.5.15 Diagnosed Prevalent Cases of Late Wet AMD

2.5.16 Diagnosed Prevalent Cases of GA

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 Primary Research – Prescriber Survey

3.3 About the Authors

3.3.1 Epidemiologist

3.3.2 Reviewers

3.3.3 Global Director of Therapy Analysis and Epidemiology

3.3.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

Table

Table 1: Summary of Changes to Data Types and Countries

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbid Conditions Associated with AMD

Table 4: High-Prescribing Physicians (KOL and non-KOLs) Surveyed, By Country

Figures

Figure 1: 7MM, Total Prevalent Cases of AMD, Both Sexes, N, Ages ≥50 Years, 2021 and 2031

Figure 2: 7MM, Diagnosed Prevalent Cases of AMD, Both Sexes, N, Ages ≥50 Years, 2021 and 2031

Figure 3: 7MM, Total Prevalence of AMD, Men and Women, Ages ≥50 Years, %, 2021

Figure 4: 7MM, Diagnosed Prevalence of AMD, Men and Women, Ages ≥50 Years, 2021

Figure 5: 7MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD

Figure 6: 7MM, Sources Used to Forecast the Total Prevalent Cases of GA and Diagnosed Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, and Late Wet AMD

Figure 7: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 8: 7MM, Total Prevalent Cases of AMD by Age, Both Sexes, N, 2021

Figure 9: 7MM, Total Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N, 2021

Figure 10: 7MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 11: 7MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 12: 7MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 13: 7MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 14: 7MM, Total Prevalent Cases of GA, Both Sexes, Ages ≥50 Years, N, 2021

Figure 15: 7MM, Diagnosed Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 16: 7MM, Diagnosed Prevalent Cases of AMD by Age, Both Sexes, N, 2021

Figure 17: 7MM, Diagnosed Prevalent Cases of AMD, by Sex, Ages ≥50 Years, N, 2021

Figure 18: 7MM, Diagnosed Prevalent Cases of Early AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 19: 7MM, Diagnosed Prevalent Cases of Late AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 20: 7MM, Diagnosed Prevalent Cases of Late Dry AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 21: 7MM, Diagnosed Prevalent Cases of Late Wet AMD, Both Sexes, Ages ≥50 Years, N, 2021

Figure 22: 7MM, Diagnosed Prevalent Cases of GA, Both Sexes, Ages ≥50 Years, N, 2021

Frequently asked questions

Age-Related Macular Degeneration Epidemiology Analysis and Forecast, 2021-2031 thematic reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Age-Related Macular Degeneration Epidemiology Analysis and Forecast, 2021-2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Age-Related Macular Degeneration Epidemiology Analysis and Forecast, 2021-2031 in real time.

  • Access a live Age-Related Macular Degeneration Epidemiology Analysis and Forecast, 2021-2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.